Sangamo Biosciences (($SGMO)) has held its Q3 earnings call. Read on for the main highlights of the call. Sangamo Biosciences’ recent earnings ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ...

Sangamo Therapeutics stock has come under renewed scrutiny following recent analyst revisions to its price target. The fair value estimate has dipped from $4.10 to $3.25, with analysts adjusting ...

Qure N.V. ( ($QURE) ) has released its Q3 earnings. Here is a breakdown of the information uniQure N.V. presented to its investors. uniQure ...

uniQure N.V. (NASDAQ:QURE) on Friday released initial safety and exploratory efficacy data from the first cohort of its Phase 1/2a trial of AMT-191, an investigational gene therapy for Fabry disease.

Discover Sangamo Therapeutics’ Q3 2025 highlights: clinical progress in Fabry disease, FDA support for ST-920, extended cash runway, and partnership updates.

Background Fabry disease (FD) is an X linked lysosomal disorder with ventricular myocardial involvement that drives morbidity and mortality. Early diagnosis of cardiac involvement can be difficult.

Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits ...

In September, we presented promising detailed clinical data from a registrational STAR study in Fabry disease demonstrating ...

RICHMOND, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced detailed data from the registrational Phase 1/2 STAAR study ...